Bold endeavour(Source: Red Orbit, Marcial: BioSante May Be Buyout Bait)
Biosante, by involving in the development of a drug that restores a woman's sexual desire, has decided to take a step that both Procter & Gamble and Pfizer feared to take.
Analysts have shown extreme optimism by stating that a company looking to acquire Biosante may even have to hit the $11 a share mark. This has obviously steered investor attention after Biosante appointed Deutsche Bank to pan out a strategy.
An eye must be kept on this stock close to late 2009, which is when the phase III results are expected to be revealed.